Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. trimmed its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,756 shares of the company’s stock after selling 693 shares during the quarter. Corebridge Financial Inc.’s holdings in Amphastar Pharmaceuticals were worth $573,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock valued at $43,000 after buying an additional 348 shares during the period. Northern Trust Corp boosted its position in shares of Amphastar Pharmaceuticals by 5.1% during the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock worth $22,767,000 after purchasing an additional 29,808 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Amphastar Pharmaceuticals by 23.0% in the 4th quarter. Jane Street Group LLC now owns 99,487 shares of the company’s stock worth $3,694,000 after buying an additional 18,573 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Amphastar Pharmaceuticals by 1.0% in the 4th quarter. Ameriprise Financial Inc. now owns 146,015 shares of the company’s stock worth $5,422,000 after buying an additional 1,417 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $256,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Trading Up 0.8%

Shares of AMPH stock opened at $29.42 on Monday. The firm has a market cap of $1.37 billion, a P/E ratio of 11.02 and a beta of 0.80. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. The firm’s 50-day simple moving average is $25.21 and its 200-day simple moving average is $25.67.

Analysts Set New Price Targets

AMPH has been the topic of several recent research reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Bank of America upped their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 26th. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. Finally, Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.